Skip to main content

A preliminary study on natural killer activity in0 patients with gynecologic malignancies

Summary

A release assay of125IUdR-labelled K562 cells as target cells was performed for measuring natural killer (NK) activity of mononuclear cells in the peripheral blood of 92 cases, including 42 healthy women, 22 patients with gynecological benign tumors, and 28 patients with gynecological malignancies. The NK activity of malignant tumor group was obviously lower than that of healthy women and of benign tumor group, suggesting that a defective NK activity was present in the patients with gynecological malignancies. The NK activity in patients with ovarian malignant tumors was much lower than in those with cervical cancer, the difference being of statistical significance. In this study the leukocyte interferon was investigated for its effects on the NK activity of peripheral blood mononuclear cells from 4 cases of gynecological malignancies. The level of NK activity ascended significantly in every case nearly to normal. The augmentation of NK activity by interferon may be used as a new immunotherapy for gynecological malignancies.

This is a preview of subscription content, access via your institution.

References

  1. (NK) I. 125IUdR NK 1983;3: 272–7.

    Google Scholar 

  2. Haller O, et al. Role of non-conventional natural killer cells in resistance against syngeneic tumor cells in vivo. Nature 1977;270:609–11.

    PubMed  Article  CAS  Google Scholar 

  3. Shau H, et al. Human natural killing against ovarian carcinoma. Br J Cancer 1988;47:687–95.

    Google Scholar 

  4. Herberman RH, et al. Natural killer cell: heir role in defenses against disease. Science 1981;214:24–30.

    PubMed  Article  CAS  Google Scholar 

  5. Riesenfeld I, et al. Positive correlation between in vitro NK activity and in vivo resistance towards AKR lymphoma cells. Int J Cancer 1980;25:399–403.

    PubMed  Article  CAS  Google Scholar 

  6. Talmadge JE, et al. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980;284: 622–4.

    PubMed  Article  CAS  Google Scholar 

  7. Kassai M, et al. Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo. J Exp Med 1979;149: 1260–4.

    Article  Google Scholar 

  8. 1984;3: 103–5.

  9. 1985;2:83–6.

  10. Schattner A, et al. Natural killer cells —toward clinical application. Am J Hematol 1985;18:435–43.

    PubMed  Article  CAS  Google Scholar 

  11. Hamilton TC, et al. Biologic therapy for treatment of malignant common epithelial tumors of the ovary. Cancer 1987;60(8 suppl): 2054–63.

    PubMed  CAS  Google Scholar 

  12. Lotzowa E, et al. Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer. Int J Cancer 1988;43:225–31.

    Article  Google Scholar 

  13. Lichtenstein A, et al. Intraperitoneal administration of human recombinant interferon-α in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res 1988;48: 5853–9.

    PubMed  CAS  Google Scholar 

  14. Boyer PJ, et al. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients. Obstet Gynecol 1989;73: 793–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ding, M., Mei-jiao, G. & Bai-qing, L. A preliminary study on natural killer activity in0 patients with gynecologic malignancies. Journal of Tongji Medical University 10, 159–163 (1990). https://doi.org/10.1007/BF02986455

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02986455

Key words

  • gynecologic malignancies
  • NK activity
  • interferon